An open-label evaluator-blinded clinical study of minocycline neuroprotection in ischemic stroke: gender-dependent effect
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Minocycline as an antibiotic has been found to have neuroprotective effect on neurodegenerative diseases. This study was aimed at determining the efficacy of minocycline adjunct to aspirin in improving neurological outcomes of ischemic stroke during 3-month follow-up. METHODS AND MATERIALS: In an open-label evaluator-blinded trial, 60 patients with ischemic stroke were allocated into two groups to receive either 200 mg of oral minocycline daily for 5 days during 6-24 h following onset of signs and symptoms, or not receiving any, as control; all patients also received 100 mg of aspirin daily. Clinical assessment at baseline and on days 30, 60, and 90 was performed using National Institutes of Health Stroke Scale (NIHSS) score. RESULTS: Fifty-three patients (88.3%) completed the study. Females in the treatment and control groups were 53.8% and 51.9%, respectively (P = 0.884). Among all patients, NIHSS score was significantly lower in the minocycline-treated compared with control on day 90 (minocycline median 4, interquartile range 4-7, control median 7, interquartile range 5-8, P = 0.031). Among males, NIHSS was lower in minocycline-treated compared with controls on days 30, 60, and 90 (P < 0.05); however, females showed no significant differences at the same times compared with controls. No adverse outcomes including myocardial infarction, recurrent stroke, and mortality were observed in the both groups. CONCLUSION: Patients with ischemic stroke who received oral minocycline daily for 5 days had significantly better neurological outcomes on day 90 than controls. However, females showed no significant clinical improvement compared to males.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sacco, R. L., Kasner, S. E., Broderick, J. P., Caplan, L. R., Connors, J. J. (., Culebras, A., Elkind, M. S. V., George, M. G., Hamdan, A. D., Higashida, R. T., et al. (2013) · Stroke · doi:10.1161/str.0b013e318296aeca · Cited by 3,569 · cited 1×
“Because of increase in population age, stroke burden will increase during the following 20 years (1), and based on the latest global burden of disease, up to 2010 year, it has been considered as the third most common cause of death and disability worldwide (2).”
BackgroundInfluentialMeasuring the global burden of disease
Murray, C. J. L., & Lopez, A. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1201534 · Cited by 1,818 · cited 1×
“Because of increase in population age, stroke burden will increase during the following 20 years (1), and based on the latest global burden of disease, up to 2010 year, it has been considered as the third most common cause of death and disability worldwide (2).”
BackgroundInfluentialTetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Minocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
Cited by
Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke
Xiong, X.-Y., Liu, L., & Yang, Q.-W. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.05.001 · Cited by 701
Age and Sex Are Critical Factors in Ischemic Stroke Pathology
Roy-O’Reilly, M., & McCullough, L. D. (2018) · Endocrinology · doi:10.1210/en.2018-00465 · Cited by 460
White matter injury in ischemic stroke
Wang, Y., Liu, G., Hong, D., Chen, F., Ji, X., & Cao, G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.005 · Cited by 309
Sex differences in stroke: Challenges and opportunities
Bushnell, C. D., Chaturvedi, S., Gage, K. R., Herson, P. S., Hurn, P. D., Jiménez, M. C., Kittner, S. J., Madsen, T. E., McCullough, L. D., McDermott, M., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18793324 · Cited by 305
Microglia–blood vessel interactions: a double-edged sword in brain pathologies
Dudvarski Stankovic, N., Teodorczyk, M., Ploen, R., Zipp, F., & Schmidt, M. H. H. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1524-y · Cited by 301
Sex differences in the brain: Implications for behavioral and biomedical research
Choleris, E., Galea, L. A. M., Sohrabji, F., & Frick, K. M. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.005 · Cited by 214
Sex differences in neuroinflammation and neuroprotection in ischemic stroke
Spychala, M. S., Honarpisheh, P., & McCullough, L. D. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23962 · Cited by 127
“The beneficial effects of Minocycline were solely driven by the beneficial response observed in men (Amiri-Nikpour et al., 2015).”
BackgroundThe Translational Potential of Microglia and Monocyte-Derived Macrophages in Ischemic Stroke
Wicks, E. E., Ran, K. R., Kim, J. E., Xu, R., Lee, R. P., & Jackson, C. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.897022 · Cited by 92
Acosta-Martínez, M. (2020) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.264598 · Cited by 51
Lyu, Y., Meng, Z., Hu, Y., Jiang, B., Yang, J., Chen, Y., Zhou, J., Li, M., & Wang, H. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1394932 · Cited by 42
Metadata
- Authors
- Amiri-Nikpour, M. R., Nazarbaghi, S., Hamdi-Holasou, M., & Rezaei, Y.
- Venue
- Acta Neurologica Scandinavica
- Publisher
- Hindawi Limited
- Published
- 2014-08-23
- Volume
- 131
- Issue
- 1
- Pages
- 45-50
- ISSN
- 0001-6314 (ISSN-L)
- OpenAlex
- W1984441940
- Cited by
- 115
- References
- 5
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.